Hackensack Meridian Mountainside Medical Center has been given the green light to use a new type of therapy for prostate cancer, the Montclair facility announced Nov. 15.
Approved by the U.S. Food and Drug Administration, Pluvicto is the only targeted radioligand therapy for treatment of metastatic prostate-specific membrane antigen positive castration-resistant prostate cancer (PSMA+ mCRPC). According to Mountainside Medical, it is the first facility in New Jersey to offer treatment using this technology.
“Pluvicto emits radioactive agents that target PSMA+ cancer cells in the body,” Dr. Brett Lewis, medical director of radiation oncology at Mountainside Medical, explained in a statement. “This precision limits damage to other cells and improve[s] outcomes for patients. This innovation is life-changing for our patients and their loved ones.”
According to the American Cancer Society, prostate cancer is the most common cancer in men in the U.S., with an estimated 268,490 new cases and 34,500 deaths projected for 2022. In New Jersey, the ACS estimates there were 8,580 new cases in New Jersey this year, and 750 deaths.
Studies found that patients treated with Pluvicto as well as androgen receptor pathway inhibition and taxane-based chemotherapy had a 38% reduction in risk of death compared with the latter two therapies alone, according to Mountainside Medical.
Dr. James Orsini, hematology oncologist at Mountainside Medical, added that Pluvicto, along with the facility’s new cancer imaging technology unveiled in July, “significantly improve survival for patients who have already been treated with other anticancer treatments.”
Mountainside Medical CEO Tim O’Brien added, “Bringing the latest, targeted cancer therapies to our hospital means that our local community has access to the advanced care options they need, closer to home.”
Mountainside Medical has been serving Montclair and the surrounding communities since 1891. In addition to its numerous medical offerings, it is one of only a few community hospitals licensed by the state to perform emergency and elective cardiac angioplasty.